Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

To evaluate the safety of mitoxantrone hydrochloride liposome combined with enlonstobart in the treatment of relapsed or refractory peripheral T-cell lymphoma, to determine the optimal dosage of mitoxantrone hydrochloride liposome within the combination regimen, and to assess the efficacy of the combined therapy.

NCT Number	NCT07288814
Lead Sponsor	Sun Yat-Sen University Cancer Center Collaborators: CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions	Relapsed or Refractory Peripheral T Cell Lymphoma
Enrollment	43 participants
Start Date	2025-12-08
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-17